A Phase I Trial of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients With Inoperable Stage I Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2018
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 11 Dec 2017 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.
- 11 Dec 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
- 17 Feb 2016 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.